Aurora Cannabis Acquires Safari Flower to Expand International EU-GMP Capacity

EDMONTON – Aurora Cannabis Inc. announced that it has acquired Safari Flower Co., an established white-label, EU-GMP-certified Cannabis cultivator and manufacturer based in Ontario.

Aurora purchased 100% of the shares of 9869247 Canada Limited, operating as Safari Flower Co., for aggregate consideration valued at $26.5 million, subject to customary adjustments. The payment included $15 million in cash at closing and the issuance of 2,417,180 common shares to the seller. An additional $2 million in cash remains contingent on certain post-closing conditions.

Safari Flower runs a 59,000-square-foot indoor facility focused on high-quality Cannabis cultivation and manufacturing. The site holds EU-GMP certification, which allows production of pharmaceutical-grade material suitable for regulated international [EU and South Pacific] medical markets.

Aurora plans to integrate the new capacity into its existing network of GMP-certified sites in Canada and Germany. The added output will support shipments to established medical markets in Germany, Australia, Poland, and the United Kingdom, as well as potential new territories. Company officials described the move as a way to increase supply of EU-GMP-compliant flower without constructing new facilities.

Miguel Martin, Aurora’s executive chairman and CEO, said in a statement that the acquisition represents a step in expanding capacity to meet demand in regulated international markets. He noted the company would apply its plant-science and operations experience to improve yields and efficiency once the assets are folded into Aurora’s supply chain.

The deal is projected to add to Aurora’s adjusted EBITDA starting in the fiscal year that ends in March 2027, with further gains expected in 2028 as operations are optimized.

Safari Flower, which once operated under creditor protection before exiting successfully in September 2024, had positioned itself as a contract manufacturer focused on export-grade product. Its EU-GMP status, granted with technical support from partners like Enua Pharma GmbH, made it one of a limited number of Canadian facilities able to ship directly into European medical channels.

For Aurora, the purchase continues a pattern of measured international expansion. The company has reported steady growth in medical Cannabis revenue outside Canada in recent quarters, where margins tend to exceed those in the domestic recreational market. With a clean balance sheet on the Cannabis side and positive free cash flow, Aurora has room to absorb the modest equity and cash outlay, which represents roughly 13% of its current market capitalization.

The acquisition closes a chapter for Safari Flower Co. while giving Aurora immediate scale in a segment that requires strict compliance and traceability. Aurora, focused on profitable global medical Cannabis growth, gains proven EU-GMP infrastructure and a ready supply line for higher-margin export business without the time or capital required to build from scratch.